Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.

Original reporting
Published Oct 15, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 6:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AQST
Bullish
medium confidence
Mentioned
$AQST
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AQSTBullishMed
01

Why it matters

FDA acceptance of the resubmitted NDA as complete and Class 2 meaningfully advances the regulatory process and establishes a clear PDUFA goal date for review completion.

02

Market read

Traders can update probability-weighted expectations for an Anaphylm approval decision ahead of the first quarter 2027 window tied to the March 16, 2027 PDUFA goal date.

03

What to watch

The article does not disclose what specific issues were addressed from the prior Complete Response Letter, so traders may still discount the probability of approval until more detailed FDA feedback or clinical/regulatory updates emerge.

Relevance 7/10Novelty 7/10Timing: PDUFA review clock set, with FDA review completion targeted for March 16, 2027.

Background

Anaphylm (dibutepinephrine) is a polymer matrix-based, needle-free sublingual epinephrine oral film intended for rapid treatment of anaphylaxis.

Company-level read

Ticker impact

$AQSTBullishMedium confidence
Context

FDA accepted Aquestive’s Anaphylm NDA resubmission as a complete Class 2 response and set a PDUFA goal date of March 16, 2027.

Expected impact

Likely upward bias as traders price improved odds of eventual approval and a defined review schedule.

Evidence & confidence

The article reports a concrete FDA procedural milestone (acceptance, Class 2 classification, and PDUFA goal date), which typically improves visibility versus a pending or incomplete filing.

Market effects

Highlights ongoing FDA review progress for epinephrine delivery alternatives, a niche within specialty pharma and allergy/emergency care.

Primarily US regulatory-driven sentiment for the biotech/specialty pharma complex.

Limited direct global spillover, but reinforces FDA’s continued scrutiny and process timelines for acute-care therapeutics.

Counterpoint

Acceptance does not equal approval; Class 2 still implies the FDA may require additional work or could ultimately reject the NDA.

Key entities

  • Aquestive Therapeutics

    US-listed developer of Anaphylm, whose NDA resubmission was accepted by the FDA.

  • FDA

    Accepted the Anaphylm NDA resubmission as complete and set the PDUFA goal date.

  • Anaphylm (dibutepinephrine)

    Sublingual oral film formulation of epinephrine for severe allergic reactions/anaphylaxis.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.